These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 16796971)

  • 1. [Gefitinib-induced perforating dermatosis].
    Fernández-Guarino M; Aldanondo I; González-García C; Garrido P; Marquet A; Pérez-García B; Jaén P
    Actas Dermosifiliogr; 2006 Apr; 97(3):208-11. PubMed ID: 16796971
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gefitinib for a poor performance status patient with squamous cell carcinoma of the lung harboring EGFR mutation.
    Tanaka K; Hata A; Kida Y; Kaji R; Fujita S; Katakami N; Imai Y
    Intern Med; 2012; 51(6):659-61. PubMed ID: 22449680
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Contribution to acneiform eruptions by epidermal growth factor receptor inhibitors].
    Bodet D; Bartralot R; Mollet J; Heras C; García-Patos V
    Actas Dermosifiliogr; 2006 Mar; 97(2):148-9. PubMed ID: 16595122
    [No Abstract]   [Full Text] [Related]  

  • 4. Purpuric Drug Eruptions Caused by Epidermal Growth Factor Receptor Inhibitors for Non-Small Cell Lung Cancer: A Clinicopathologic Study of 32 Cases.
    Cho YT; Chen KL; Sheen YS; Yang CW; Liau JY; Cheng YP; Chu CY
    JAMA Dermatol; 2017 Sep; 153(9):906-910. PubMed ID: 28538945
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exacerbation of psoriasis after treatment with an EGFR tyrosine kinase inhibitor.
    Zorzou MP; Stratigos A; Efstathiou E; Bamias A
    Acta Derm Venereol; 2004; 84(4):308-9. PubMed ID: 15339078
    [No Abstract]   [Full Text] [Related]  

  • 6. Learning from errors: response to gefitinib in kidney urothelial carcinoma with EGFR mutations.
    Fiorentino M; Giunchi F; Altimari A; Di Tullio P; Gruppioni E; Martorana G; Pinto C
    Oncologist; 2014 Apr; 19(4):430. PubMed ID: 24652385
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Erlotinib-induced acneiform rash not affecting previously irradiated skin].
    Eguren C; Domínguez-Fernández I; Santiago-Sánchez-Mateos DI; García-Díez A
    Actas Dermosifiliogr; 2010 Mar; 101(2):186-7. PubMed ID: 20223168
    [No Abstract]   [Full Text] [Related]  

  • 8. [Gefitinib treatment for carcinomatous meningitis in non-small cell lung cancer].
    Chouahnia K; Brechot JM; Des-Guetz G; Saintigny P; Morere JF; Breau JL
    Rev Mal Respir; 2006 Apr; 23(2 Pt 1):149-51. PubMed ID: 16788439
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pneumonectomy after response to gefitinib treatment for lung adenocarcinoma.
    Funakoshi Y; Takeuchi Y; Maeda H
    Asian Cardiovasc Thorac Ann; 2013 Aug; 21(4):482-4. PubMed ID: 24570539
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized Phase III Study Comparing Gefitinib With Erlotinib in Patients With Previously Treated Advanced Lung Adenocarcinoma: WJOG 5108L.
    Urata Y; Katakami N; Morita S; Kaji R; Yoshioka H; Seto T; Satouchi M; Iwamoto Y; Kanehara M; Fujimoto D; Ikeda N; Murakami H; Daga H; Oguri T; Goto I; Imamura F; Sugawara S; Saka H; Nogami N; Negoro S; Nakagawa K; Nakanishi Y
    J Clin Oncol; 2016 Sep; 34(27):3248-57. PubMed ID: 27022112
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gefitinib (Iressa, ZD1839) and tyrosine kinase inhibitors: the wave of the future in cancer therapy.
    Penne K; Bohlin C; Schneider S; Allen D
    Cancer Nurs; 2005; 28(6):481-6. PubMed ID: 16330971
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.
    Takeda M; Okamoto I; Tsurutani J; Oiso N; Kawada A; Nakagawa K
    Jpn J Clin Oncol; 2012 Jun; 42(6):528-33. PubMed ID: 22457323
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gefitinib monotherapy in chemotherapy-naive patients with inoperable stage III/IV non-small-cell lung cancer.
    Reck M; Buchholz E; Romer KS; Krutzfeldt K; Gatzemeier U; Manegold C
    Clin Lung Cancer; 2006 May; 7(6):406-11. PubMed ID: 16800967
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Markers in the epidermal growth factor receptor pathway and skin toxicity during erlotinib treatment.
    Tan AR; Steinberg SM; Parr AL; Nguyen D; Yang SX
    Ann Oncol; 2008 Jan; 19(1):185-90. PubMed ID: 17878175
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Concurrent radiotherapy with gefitinib in elderly patients with esophageal squamous cell carcinoma: Preliminary results of a phase II study.
    Xu Y; Zheng Y; Sun X; Yu X; Gu J; Wu W; Zhang G; Hu J; Sun W; Mao W
    Oncotarget; 2015 Nov; 6(35):38429-39. PubMed ID: 26392415
    [TBL] [Abstract][Full Text] [Related]  

  • 16. First-line gefitinib treatment in elderly patients (aged ≥75 years) with non-small cell lung cancer harboring EGFR mutations.
    Kuwako T; Imai H; Masuda T; Miura Y; Seki K; Yoshino R; Kaira K; Utsugi M; Shimizu K; Sunaga N; Tomizawa Y; Ishihara S; Ishizuka T; Mogi A; Hisada T; Minato K; Takise A; Saito R; Yamada M
    Cancer Chemother Pharmacol; 2015 Oct; 76(4):761-9. PubMed ID: 26254024
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EGFR mutation L747P led to gefitinib resistance and accelerated liver metastases in a Chinese patient with lung adenocarcinoma.
    Yu G; Xie X; Sun D; Geng J; Fu F; Zhang L; Wang H
    Int J Clin Exp Pathol; 2015; 8(7):8603-6. PubMed ID: 26339441
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Leukocyte Telomere Length and Clinical Outcomes of Advanced Lung Adenocarcinoma Patients with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Treatment.
    Li J; Zhang L; Zhu H; Pan W; Zhang N; Li Y; Yang M
    DNA Cell Biol; 2018 Nov; 37(11):903-908. PubMed ID: 30277797
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gefitinib therapy for non-small cell lung cancer.
    Birnbaum A; Ready N
    Curr Treat Options Oncol; 2005 Jan; 6(1):75-81. PubMed ID: 15610717
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Follicular and epidermal alterations in patients treated with ZD1839 (Iressa), an inhibitor of the epidermal growth factor receptor.
    Van Doorn R; Kirtschig G; Scheffer E; Stoof TJ; Giaccone G
    Br J Dermatol; 2002 Sep; 147(3):598-601. PubMed ID: 12207609
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.